Market Research Logo

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015’, provides an overview of the Multiple Myeloma (Kahler's Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler's Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Multiple Myeloma (Kahler's Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Multiple Myeloma (Kahler's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Multiple Myeloma (Kahler's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler's Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler's Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Multiple Myeloma (Kahler's Disease) Overview
Therapeutics Development
Multiple Myeloma (Kahler's Disease) – Therapeutics under Development by Companies
Multiple Myeloma (Kahler's Disease) – Therapeutics under Investigation by Universities/Institutes
Multiple Myeloma (Kahler's Disease) – Pipeline Products Glance
Multiple Myeloma (Kahler's Disease) – Products under Development by Companies
Multiple Myeloma (Kahler's Disease) – Products under Investigation by Universities/Institutes
Multiple Myeloma (Kahler's Disease) – Companies Involved in Therapeutics Development
Multiple Myeloma (Kahler's Disease) – Therapeutics Assessment
Drug Profiles
Multiple Myeloma (Kahler's Disease) – Recent Pipeline Updates
Multiple Myeloma (Kahler's Disease) – Dormant Projects
Multiple Myeloma (Kahler's Disease) – Discontinued Products
Multiple Myeloma (Kahler's Disease) – Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Multiple Myeloma (Kahler's Disease), H1 2015
Number of Products under Development for Multiple Myeloma (Kahler's Disease) – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Development by Companies, H1 2015 (Contd..9)
Number of Products under Development by Companies, H1 2015 (Contd..10)
Number of Products under Development by Companies, H1 2015 (Contd..11)
Number of Products under Investigation by Universities/Institutes, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Development by Companies, H1 2015 (Contd..14)
Products under Development by Companies, H1 2015 (Contd..15)
Products under Development by Companies, H1 2015 (Contd..16)
Products under Development by Companies, H1 2015 (Contd..17)
Products under Development by Companies, H1 2015 (Contd..18)
Products under Development by Companies, H1 2015 (Contd..19)
Products under Development by Companies, H1 2015 (Contd..20)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2)
Multiple Myeloma (Kahler's Disease) – Pipeline by 4SC AG, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by AB Science, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by AbbVie Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Ablynx NV, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Acceleron Pharma, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Adaptimmune Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Advancell, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Affimed Therapeutics AG, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Altor BioScience Corporation, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Amgen Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Amorfix Life Sciences Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by APIM Therapeutics AS, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by APO-T B.V., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Aptose Biosciences Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Arcarios BV, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Arno Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Array BioPharma Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Astellas Pharma Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Aurigene Discovery Technologies Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by AvidBiotics Corp., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Axelar AB, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Bayer AG, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Biogenomics Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by BioInvent International AB, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by BioNovion B.V., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Biotest AG, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Bluebird bio, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Boston Biomedical, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Bristol-Myers Squibb Company, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Calithera Biosciences, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Celgene Corporation, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Cellectar Biosciences, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Cellectis S.A., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Cellerant Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Celleron Therapeutics Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Celyad, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by ChemoCentryx, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Compugen Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Concert Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Constellation Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by CureTech Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Curis, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by DARA BioSciences, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Eli Lilly and Company, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Enceladus Pharmaceuticals BV, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Exelixis, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Fortress Biotech, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Gamida Cell Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Genentech, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by GlaxoSmithKline Plc, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Gliknik, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Hutchison MediPharma Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Immune System Therapeutics Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Immunocore Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Immunomedics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Immunomic Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Incyte Corporation, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Innate Pharma SA, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Jasco Pharmaceuticals, LLC., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Johnson & Johnson, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by JW Pharmaceutical Corporation, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Kancera AB, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by MandalMed, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by MedImmune, LLC, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Merck & Co., Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Merus B.V., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Mirna Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Modulation Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Molecular Templates Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by MolMed S.p.A., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by MorphoSys AG, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Nippon Kayaku Co., Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Nordic Nanovector ASA, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Novartis AG, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Noxxon Pharma AG, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Oncolytics Biotech Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Onconova Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by OncoPep Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Oncopeptides AB, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Onyx Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Panacela Labs, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Patrys Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Pfizer Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Pharma Mar, S.A., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Pharmacyclics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Polyphor Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Pono Pharma, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Prescient Therapeutics Ltd, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Priaxon AG, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Progenra, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Prolexys Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Quest PharmaTech Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Rhizen Pharmaceuticals SA, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Sanofi, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Selexys Pharmaceuticals Corporation, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Senhwa Biosciences, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Sigma-Tau S.p.A., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Stemline Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Synta Pharmaceuticals Corp., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Targazyme, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by TG Therapeutics, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Theravectys S.A., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Tragara Pharmaceuticals, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Transgene Biotek Limited, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Vaccibody AS, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Vaccinex, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Vaxil Bio Therapeutics Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Verastem, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Vivolux AB, H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by XBiotech USA, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Xencor, Inc., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by XTL Biopharmaceuticals Ltd., H1 2015
Multiple Myeloma (Kahler's Disease) – Pipeline by Zyngenia, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Multiple Myeloma (Kahler's Disease) Therapeutics – Recent Pipeline Updates, H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects, H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..1), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..2), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..3), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..4), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..5), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..6), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..7), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..8), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..9), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..10), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..11), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..12), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..13), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..14), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..15), H1 2015
Multiple Myeloma (Kahler's Disease) – Dormant Projects (Contd..16), H1 2015
Multiple Myeloma (Kahler's Disease) – Discontinued Products, H1 2015
Multiple Myeloma (Kahler's Disease) – Discontinued Products (Contd..1), H1 2015
Multiple Myeloma (Kahler's Disease) – Discontinued Products (Contd..2), H1 2015
Multiple Myeloma (Kahler's Disease) – Discontinued Products (Contd..3), H1 2015
Multiple Myeloma (Kahler's Disease) – Discontinued Products (Contd..4), H1 2015
List of Figures
Number of Products under Development for Multiple Myeloma (Kahler's Disease), H1 2015
Number of Products under Development for Multiple Myeloma (Kahler's Disease) – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report